TABLE 2.—ESTIMATED ANNUAL RECORDKEEPING BURDEN[1]

Standard No.	No. of Record-keepers	Annual Frequency per Record-keeping	Total Annual Records	Hours per Record-keeper	Total Hours
3, 4, and 6[2]	500	1	500	5	2,500

[1]There are no capital costs or operating and maintenance costs associated with this collection of information.
[2]The standards incorporate the best program management practices currently in use in the regulatory community. The recommended policies, procedures, and standard operating procedures contained in the various national standards are considered usual and customary management practices for State, local, and tribal agencies that regulate the retail segment of the food industry.

Dated: May 4, 2001.

William K. Hubbard,

Senior Associate Commissioner for Policy, Planning, and Legislation.

[FR Doc. 01–11618 Filed 5–8–01; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 99D–0239]

Agency Information Collection Activities; Announcement of OMB Approval; Request for Resolution of Scientific Disputes Concerning the Regulation of Medical Devices

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that a collection of information entitled ''Request for Resolution of Scientific Disputes Concerning the Regulation of Medical Devices'' has been approved by the Office of Management and Budget (OMB) under the Paperwork Reduction Act of 1995.

FOR FURTHER INFORMATION CONTACT: Peggy Schlosburg, Office of Information Resources Management (HFA–250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–1223.

SUPPLEMENTARY INFORMATION: In the **Federal Register** of February 8, 2001 (66 FR 9585), the agency announced that the proposed information collection had been submitted to OMB for review and clearance under 44 U.S.C. 3507. An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. OMB has now approved the information collection and has assigned OMB control number 0910–0467. The approval expires on April 30, 2004. A copy of the supporting statement for this information collection is available on the Internet at http://www.fda.gov/ohrms/dockets.

Dated: May 3, 2001.

William K. Hubbard,

Senior Associate Commissioner for Policy, Planning, and Legislation.

[FR Doc. 01–11583 Filed 5–8–01; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 01N–0179]

Purina Mills, Inc., et al.; Withdrawal of Approval of New Animal Drug Applications

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is withdrawing approval of 11 new animal drug applications (NADAs) listed below. In a final rule published elsewhere in this issue of the **Federal Register**, FDA is amending the animal drug regulations to remove the portions reflecting approval of the NADAs because the products are no longer manufactured or marketed.

DATES: Withdrawal of approval is effective May 21, 2001.

FOR FURTHER INFORMATION CONTACT: Pamela K. Esposito, Center for Veterinary Medicine (HFV–210), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301–827–5593.

SUPPLEMENTARY INFORMATION: The following sponsors have requested that FDA withdraw approval of the NADAs listed below because the products are no longer manufactured or marketed:

Sponsor	NADA No. Product (Drug)	21 CFR Cite Affected (Sponsor Drug Labeler Code)
Purina Mills, Inc., P.O. Box 66812, St. Louis, MO 63166–6812.	NADA 48–915 Purina® Bot Control (trichlorfon)	520.2520a (017800)
Golden Sun Feeds, Inc., 111 South Fifth St., Estherville, IA 51334.	NADA 97–567 Tylan® 10 Premix (tylosin phosphate).	558.625(b)(17) (021780)
.....	NADA 97–615 Swine Med-A-Mix TS 8000 Premix, Tylan® 5, 10, 20, 40 Sulfa-G (tylosin phosphate and sulfamethazine).	558.630(b)(4) and (b)(10) (021780)
Quali-Tech Products, Inc., 318 Lake Hazeltine Dr., Chaska, MN 55318–1093.	NADA 110–440 Hygromix Hygrowormer Hyanthelmix (hygromycin B).	558.274(a)(2), (a)(3), (a)(4), (c)(1)(i), and (c)(1)(ii) (016968)
Steris Laboratories, Inc., 620 North 51st Ave., Phoenix, AZ 85043–4705.	NADA 44–585 Oxytocin Injection	522.1680 (000402)
.....	NADA 45–578 Lidocaine Hydrochloride with Epi-nephrine Injection 2%.	522.1258 (000402)
.....	NADA 45–737 Sodium Pentobarbital Injection	522.1704(b) (000402)
.....	NADA 45–848 Phenylbutazone Injection	522.1720 (000402)
.....	NADA 110–349 Dexamethasone Injection	522.540(c)(2) (000402)

Sponsor	NADA No. Product (Drug)	21 CFR Cite Affected (Sponsor Drug Labeler Code)
.....	NADA 110–350 Dexamethasone Injection	522.540(b)(2)(ii) (000402)
.....	NADA 117–973 Prednisolone Sodium Succinate for Injection.	522.1884(c) (000402)

Therefore, under authority delegated to the Commissioner of Food and Drugs (21 CFR 5.10), redelegated to the Center for Veterinary Medicine (21 CFR 5.84), and in accordance with § 514.115 *Withdrawal of approval of applications* (21 CFR 514.115), notice is given that approval of NADAs 44–585, 45–578, 45–737, 45–848, 48–915, 97–567, 97–615, 110–349, 110–350, 110–440, and 117–973, and all supplements and amendments thereto, is hereby withdrawn, effective May 21, 2001.

In a final rule published elsewhere in this issue of the **Federal Register**, FDA is amending the animal drug regulations to reflect the withdrawal of approval of these NADAs.

Dated: May 2, 2001.

Stephen F. Sundlof,

Director, Center for Veterinary Medicine.

[FR Doc. 01–11620 Filed 5–8–01; 8:45 am]

BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Request for Nominations for Members on Public Advisory Committees in the Center for Drug Evaluation and Research

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is requesting nominations for members to serve on the public advisory committees in the Center for Drug Evaluation and Research. Nominations will be accepted for current vacancies and vacancies that will or may occur on the committees during the next 16 months.

FDA has a special interest in ensuring that women, minority groups, and the physically handicapped are adequately represented on advisory committees and, therefore, extends particular encouragement to nominations for appropriately qualified female, minority, and physically handicapped candidates. Final selection from among qualified candidates for each vacancy will be determined by the expertise required to meet specific agency needs and in a manner to ensure appropriate balance of membership.

DATES: Because scheduled vacancies occur on various dates throughout each year, no cutoff date is established for receipt of nominations.

ADDRESSES: All nominations and curricula vitae should be sent to the addresses below.

FOR FURTHER INFORMATION CONTACT:

Regarding nominations, except for consumer representatives: John Treacy, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–7001, e-mail: treacy@cder.fda.gov.

Regarding nominations for consumer representatives: Maureen Hess, Office of Consumer Affairs (HFE–50), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–5006, e-mail: mhess@oc.fda.gov.

SUPPLEMENTARY INFORMATION: FDA is requesting nominations of members for the following 16 advisory committees for vacancies listed below. Individuals should have expertise in the activity of the committee.

1. *Advisory Committee for Pharmaceutical Science*: Two vacancies occurring immediately, two vacancies occurring October 31, 2001, and six vacancies occurring October 31, 2002, including that of the consumer-nominated member.

2. *Advisory Committee for Reproductive Health Drugs*: Four vacancies occurring immediately, four vacancies occurring June 30, 2001, and three vacancies occurring June 30, 2002.

3. *Anesthetic and Life Support Drugs Advisory Committee*: Five vacancies occurring immediately, and four vacancies occurring March 31, 2002, including that of the consumer-nominated member.

4. *Anti-Infective Drugs Advisory Committee*: Five vacancies occurring November 30, 2001, and three vacancies occurring November 30, 2002.

5. *Antiviral Drugs Advisory Committee*: Three vacancies occurring immediately, three vacancies occurring October 31, 2001, and two vacancies occurring October 31, 2002.

6. *Arthritis Advisory Committee*: Two vacancies occurring September 30, 2001, and four vacancies occurring September 30, 2002.

7. *Cardiovascular and Renal Drugs Advisory Committee*: Three vacancies occurring June 30, 2001, including that of the consumer-nominated member, and four vacancies occurring June 30, 2003.

8. *Dermatologic Drugs Advisory Committee*: Seven vacancies occurring immediately, four vacancies occurring August 31, 2001, and four vacancies occurring August 31, 2002, including that of the consumer-nominated member.

9. *Endocrinologic and Metabolic Drugs Advisory Committee*: One vacancy occurring immediately, one vacancy occurring June 30, 2001, and four vacancies occurring June 30, 2002.

10. *Gastrointestinal Drugs Advisory Committee*: Three vacancies occurring June 30, 2001, and two vacancies occurring June 30, 2002.

11. *Medical Imaging Drugs Advisory Committee*: Ten vacancies occurring immediately, three vacancies occurring June 30, 2001, and two vacancies occurring June 30, 2002, including that of the consumer-nominated member.

12. *Nonprescription Drugs Advisory Committee*: Four vacancies occurring immediately, including that of the consumer-nominated member, one vacancy occurring on May 30, 2001, and four vacancies occurring May 31, 2002.

13. *Oncologic Drugs Advisory Committee*: Two vacancies occurring June 30, 2001, and three vacancies occurring June 30, 2002.

14. *Peripheral and Central Nervous Systems Drugs Advisory Committee*: Seven vacancies occurring immediately.

15. *Psychopharmacologic Drugs Advisory Committee*: Two vacancies occurring June 30, 2001, and four vacancies occurring June 30, 2002, including that of the consumer-nominated member.

16. *Pulmonary-Allergy Drugs Advisory Committee*: Two vacancies occurring immediately, two vacancies occurring May 31, 2001, including that of the consumer-nominated member, and five vacancies occurring May 31, 2002.

Function

The functions of the 16 committees listed above are to review and evaluate available scientific, technical, and